This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Agile Therapeutics (AGRX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Agile Therapeutics (AGRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Barrett Business Services, Hibbett Sports, Construction Partners, Agile Therapeutics and Boot Barn
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Barrett Business Services, Hibbett Sports, Construction Partners, Agile Therapeutics and Boot Barn
Trade Worries Resurface! Buy These 5 U.S. Stocks Now
by Tirthankar Chakraborty
Due to their limited international exposure, domestic firms offer more protection than their large- and mid-cap counterparts during economic upheavals.
Top Ranked Momentum Stocks to Buy for September 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 25th.
Zynerba Releases Data on Epilepsy Candidate, Stock Down
by Zacks Equity Research
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Agile Therapeutics (AGRX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Agile Therapeutics (AGRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for August 22nd
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
by Zacks Equity Research
Agile Therapeutics, Inc. (AGRX) moved big last session, as its shares rose almost 14% on the day.
WellCare Health Plans Prices Senior Notes Worth $1.2 Billion
by Zacks Equity Research
WellCare Health Plans, Inc. (WCG) issued 5.25% $1.2 billion senior notes with maturity scheduled on Apr 1, 2025.